ライフサイエンスコーパス: interleukin-6

1 nflammatory proteins (C-reactive protein and interleukin-6).

2 matory markers (tumor necrosis factor-alpha, interleukin-6).

3 versible peaks in plasma levels of renin and interleukin 6.

4 ng extreme elevations of KSHV viral load and interleukin 6.

5 ion of XBP1, and that this activity requires interleukin 6.

6 y weight, and elevated levels of circulating interleukin 6.

7 lar macrophages (AMs) that produce increased interleukin-6.

8 leocapsid antibody nor with proteins such as interleukin-6.

9 bility in newly activated CD8(+) T cells via interleukin-6.

10 ecrosis factor-alpha, interleukin-1beta, and interleukin-6.

11 nhibitors of tumor necrosis factor-alpha and interleukin-6.

12 macrophage inflammatory protein 1alpha, and interleukin 6, 12p70, 8, 4, 10, and 17.

13 Serum interleukin-6 (23.1+/-4.5 pg/mL versus 6.5+/-5.8 pg/mL;

14 ferritin (706.9 vs. 334.2 mg/mL; P < 0.01), interleukin-6 (233.9 vs. 174.7 pg/mL; P < 0.05), troponi

15 Interleukin-6 (-24.9 pg/mL vs 442.8 pg/mL; P = .032) con

16 At hospital discharge, interleukin-6, -8, and -10 retained the association but

17 Interleukin-6, -8, and -10, tumor necrosis factor-alpha,

18 psis diagnosis and study intervention group, interleukin-6, -8, and -10, tumor necrosis factor-alpha,

19 ve protein, tumor necrosis factor-alpha, and interleukins-6, -8, and -10-which were averaged to form

20 umor necrosis factor-alpha (+53%; p = 0.02), interleukin-6 (+91%; p = 0.03), and interleukin-8 (+42%;

21 2.94 [1.48-5.84]), higher concentrations of interleukin-6 (aHR 1.11 [95%CI 1.02-1.20] per decile inc

22 ssociated among HIV-infected men with higher interleukin 6 and high-sensitivity C-reactive protein an

23 h as augmented microglial numbers, increased interleukin 6 and interleukin 1 receptor antagonist mess

24 al adjustments for circulating levels of IL (interleukin)-6 and high-sensitivity CRP (C-reactive prot

25 Interleukin-6 and -10, tumor necrosis factor-alpha, and

26 Stress-induced interleukin-6 and high-frequency heart rate variability

27 aphics, risk factors, and baseline levels of interleukin-6 and high-frequency heart rate variability,

28 lomerular filtration rate (eGFR), NT-proBNP, interleukin-6 and high-sensitive CRP as covariates.

29 Adjusting for NT-proBNPeGFR or inflammation (interleukin-6 and high-sensitive CRP) confirmed results.

30 ion of colchicine attenuated the increase in interleukin-6 and high-sensitivity C-reactive protein co

31 hat females with Down syndrome had increased interleukin-6 and interleukin-8 levels compared to males

32 h controls for the proinflammatory cytokines interleukin-6 and interleukin-8.

33 ity was independently associated with higher interleukin-6 and lower high-frequency heart rate variab

34 revented induction of inflammatory cytokines interleukin-6 and osteopontin, lowered plasma endothelin

35 biomarker model included angiopoietin-2 and interleukin-6 and performed moderately well (area under

36 Messenger RNA expression of interleukin-6 and the costimulatory molecules CD40 and i

37 flammatory cytokines by monocytes, including interleukin-6 and tumor necrosis factor.

38 oduction of tumor necrosis factor alpha, and interleukins 6 and 12 (IL-6 and IL-12p40, respectively)

39 ic inflammation (soluble CD163 and CD14, and interleukin 6) and levels of T-cell immune activation (H

40 droxy-2-nonenal, isoprostane), inflammation (interleukin-6) and iron status (ferritin, hepcidin, tran

41 to 3) associations between circulating IL6 (interleukin-6) and NT-proBNP (N terminal pro B-type natr

42 na and optic nerve, including complement 1q, interleukin 6, and brain-derived neurotrophic factor.

43 n in the expression levels of p21, mTOR/pS6, interleukin 6, and tumor necrosis factor alpha in skin a

44 ulation of genes involved in chemotaxis, IL (interleukin)-6, and NF-kappaB (nuclear factor-kappaB) si

45 e up-regulating tumor necrosis factor alpha, interleukin-6, and C-X-C motif chemokine ligand 1 expres

46 nflammatory cytokines (interleukin-17A, TNF, interleukin-6, and interferon-gamma).

47 ciated with the reduced expression of c-Jun, interleukin-6, and interleukin-10, which were identified

48 e expression of tumor necrosis factor alpha, interleukin-6, and interleukin-8 in the respiratory trac

49 adhesion molecule, thrombomodulin, endocan, interleukin-6, and interleukin-8 than those without acut

50 thrombomodulin, endocan, C-reactive protein, interleukin-6, and interleukin-8 were different between

51 inflammatory biomarkers (C-reactive protein, interleukin-6, and interleukin-8) were measured from per

52 poietin-2, tumor necrosis factor receptor-1, interleukin-6, and interleukin-8.

53 educed levels of systemic interleukin-1beta, interleukin-6, and monocyte chemoattractant protein-1.

54 iated with significantly lower plasma sRAGE, interleukin-6, and monocyte chemotactic protein-1 concen

55 for advanced glycation end-products, plasma interleukin-6, and monocyte chemotactic protein-1 were s

56 We found that interleukin-6- and STAT3 transcription factor-dependent

57 hil counts; increased C-reactive protein and interleukin-6; and more severe depression than the uninf

58 We used metformin treatment and anti-IL-6 (interleukin-6) antibodies to inhibit the IL-6 pathway.

59 cluding a triad of IP-10, interleukin-10 and interleukin-6, anticipate subsequent clinical progressio

60 D5Rs (DRD5KO mice) to show that carrageenan, interleukin 6, as well as BDNF-induced hyperalgesia and

61 P<0.001) and was superior and incremental to interleukin-6, C-reactive protein, procalcitonin, ferrit

62 Dural application of interleukin-6 causes acute responses in males and female

63 ed hippocampal volume, and elevated systemic interleukin-6 characterized a susceptible phenotype that

64 Higher average maternal interleukin-6 concentration during pregnancy was prospec

65 pose tissue tumour necrosis factor alpha and interleukin 6 concentrations.

66 ium, although persistent elevations in serum interleukin-6 concentrations ( P=0.009) and reductions i

67 ated the association between higher maternal interleukin-6 concentrations and lower impulse control.

68 , the primary biomarker end point, change in interleukin-6 concentrations did not differ between grou

69 onin T (hsTnT), beta-trace protein (BTP) and interleukin-6 concentrations were measured.

70 Both viral and human interleukin-6 contribute to the plasmacytic differentiat

71 ular mechanism, we identify OSM, part of the interleukin 6 cytokine family, as a HIF-1alpha target ge

72 nterconnection between the overexpression of interleukin-6 cytokine and the tumor growth, metastasis,

73 control mice, but this effect was delayed in interleukin 6-deficient mice.

74 ed that in addition to type-I interferon and interleukin-6-dependent inflammatory responses, infectio

75 ion promotes beta(2)-adrenergic-receptor(AR)-interleukin-6-dependent megakaryopoiesis.

76 Anti-interleukin-6-directed therapies are highly effective in

77 al, and cardiometabolic factors, and CRP and interleukin-6, each standard deviation increase in sCD14

78 forming growth factor beta (TGFbeta) and LIF interleukin-6 family cytokine (LIF) signaling pathways.

79 s of cardiotrophin-1 (CT-1), a member of the interleukin-6 family of cytokines.

80 ination: oncostatin M (OSM), a member of the interleukin-6 family, and downstream mediator tissue inh

81 reening was cardiotrophin-1, a member of the interleukin-6 family.

82 80) outperformed clinical markers and plasma interleukin-6 for prospectively predicting trauma patien

83 protein-1, tumor necrosis factor alpha, and interleukin-6 from mouse macrophages, while having no ef

84 r factor-kB, tumor necrosis factor-alpha and interleukin-6 gene expression in prefrontal cortex.

85 ion, and reduced plasma levels of cytokines (interleukin 6, granulocyte colony-stimulating factor, in

86 IL (Interleukin)-6 (hazard ratio, 1.26 [95% CI, 1.13-1.42]),

87 The following measurements were obtained: interleukin 6, high-sensitivity C-reactive protein, solu

88 ct effect), while, through a mediating path, interleukin 6 (IL-6) added another 49 (95% CI: 5, 94) ca

89 ological mechanical damage, via induction of interleukin 6 (IL-6) from epithelial cells, tailored eff

90 describe a new mouse strain, in which human interleukin 6 (IL-6) gene encoding the cytokine that is

91 t production of SAA depend on the release of interleukin 6 (IL-6) into the circulation by non-maligna

92 We compared neopterin, CXCL10, CCL2, and interleukin 6 (IL-6) levels in the AHI group to those in

93 Circulating interleukin 6 (IL-6) levels surge during exercise and IL

94 rkers including C-reactive protein (CRP) and Interleukin 6 (IL-6) measured in the same individuals.

95 rved that GM-CSF was not regulated by either interleukin 6 (IL-6) or IL-23, which are both potent ind

96 We used hyperalgesic priming with interleukin 6 (IL-6) priming and PGE(2) as a second stim

97 The cellular sources of interleukin 6 (IL-6) that are relevant for differentiati

98 -conditioned supernatant contained increased interleukin 6 (IL-6) that induced E-cadherin loss and N-

99 ding protein (I-FABP), soluble CD14 (sCD14), interleukin 6 (IL-6), and C-reactive protein (CRP) at 6

100 Vascular endothelial growth factor (VEGF), Interleukin 6 (IL-6), and matrix metalloproteinase-2 (MM

101 and independent from the OPN receptor CD44, interleukin 6 (IL-6), and other PMN chemoattractants inc

102 flammatory markers C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor alpha (T

103 (tumor necrosis factor alpha (TNFalpha) and interleukin 6 (IL-6), as well as Kelch-like ECH-associat

104 ion of early inflammatory markers, including interleukin 6 (IL-6), IL-1alpha, and tumor necrosis fact

105 and in vivo, including the up-regulation of interleukin 6 (IL-6), IL-23, Arginase1, as well as surfa

106 5-plex assay measuring interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 10 (IL-10), interleuki

107 nducible protein 10, soluble CD163 (sCD163), interleukin 6 (IL-6), interleukin 18, monocyte chemoattr

108 erum levels of the hepatoprotective cytokine interleukin 6 (IL-6), its downstream signal transducer a

109 cytokines and chemokine induction, including interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-a

110 tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6).

111 of matrix metalloproteases and synthesis of interleukin 6 (IL-6).

112 articles was introduced for the detection of interleukin 6 (IL-6).

113 reactive protein (Hedges's g 0.281, p<0.05), interleukin-6 (IL-6) (0.429, p<0.005), soluble tumour ne

114 NF-alpha), interleukin-1beta (IL-1beta), and interleukin-6 (IL-6) after chelation therapy.

115 pendent on exogenous soluble factors such as interleukin-6 (IL-6) and APRIL, to prevent their cell de

116 ctional associations of inflammatory markers interleukin-6 (IL-6) and C-reactive protein with major d

117 ncreased levels of the inflammatory cytokine interleukin-6 (IL-6) and decreased levels of IL-12, IFN-

118 naling mediator of many cytokines, including interleukin-6 (IL-6) and IL-10.

119 d significantly increased neonatal levels of interleukin-6 (IL-6) and IL-8 compared with GP controls.

120 mation, measured by proinflammatory cytokine interleukin-6 (IL-6) and tumor necroses factor receptor

121 they were used for the selective capture of interleukin-6 (IL-6) as targeted antigen.

122 ld application, we establish that endogenous interleukin-6 (IL-6) can be quantified in 2-uL serum sam

123 erclonal communication mechanism mediated by interleukin-6 (IL-6) cytokine secreted from EGFRvIII-pos

124 ransplantation (alloSCT) is characterized by interleukin-6 (IL-6) dysregulation.

125 ilage explants, suppressing pro-inflammatory interleukin-6 (IL-6) expression after interleukin-1 beta

126 Immunohistochemistry showed that interleukin-6 (IL-6) expression in epithelial cells of N

127 Interleukin-6 (IL-6) has emerged as a key component of t

128 n of tumor necrosis factor alpha (TNF-alpha)/interleukin-6 (IL-6) in infected kidneys.

129 Interleukin-6 (IL-6) induced hepcidin expression is a ke

130 xpression in myeloid cells, which results in interleukin-6 (IL-6) induction and STAT3 activation.

131 Interleukin-6 (IL-6) inhibition effectively treats appro

132 Interleukin-6 (IL-6) is a cytokine with critical innate

133 Interleukin-6 (IL-6) is a pleiotropic cytokine that has

134 Interleukin-6 (IL-6) is critically involved in liver reg

135 Interleukin-6 (IL-6) is elevated in circulation with chr

136 Using mouse models, we show that interleukin-6 (IL-6) is the dominant cytokine inducible

137 Interleukin-6 (IL-6) is used as a representative to exam

138 Procalcitonin and interleukin-6 (IL-6) levels were used as surrogate marke

139 ons of FITC-dextran gut translocation, serum interleukin-6 (IL-6) levels, bacteremia, and sepsis mort

140 This was closely followed by increased interleukin-6 (IL-6) levels, increased osteoclast number

141 The interleukin-6 (IL-6) membrane receptor and its circulati

142 tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) mRNAs, as well as IFN-alpha, IFN-be

143 PB interleukin-6 (IL-6) negatively correlated with endothel

144 -stroma interplay, paracrine factors such as interleukin-6 (IL-6) often facilitate disordered angioge

145 se of keratinocyte-derived cytokine (KC) and interleukin-6 (IL-6) production by cells.

146 s transiently upregulate PD-1 expression and interleukin-6 (IL-6) production in some individuals duri

147 is in OCCC cells whereby tumor-cell-produced interleukin-6 (IL-6) regulates SPINK1 expression to stim

148 expression of the pro-inflammatory cytokine interleukin-6 (IL-6) relative to BALB/cJ and PDE11A WT m

149 e response, which is enhanced by hypoxia and interleukin-6 (IL-6) signaling, two conditions that also

150 nflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the develo

151 lating microglia are critically dependent on interleukin-6 (IL-6) trans-signaling via the soluble IL-

152 17 (Th17)-cell differentiation triggered by interleukin-6 (IL-6) via STAT3 activation promotes infla

153 Interleukin-6 (IL-6) was identified as a regulator of mI

154 in 1 (CHI3L1), C-reactive protein (CRP), and interleukin-6 (IL-6) were independently validated in sep

155 e tumor necrosis factor alpha (TNF-alpha) or interleukin-6 (IL-6) were not significant.

156 des were functionalised with an antibody for interleukin-6 (IL-6) which is a protein involved in the

157 The assay was evaluated for quantitation of interleukin-6 (IL-6), a cytokine biomarker in serum.

158 ation analyses suggested that triglycerides, interleukin-6 (IL-6), and C-reactive protein (CRP) are l

159 ory cytokines interleukin-1 beta (IL-1beta), interleukin-6 (IL-6), and tumor necrosis factor-alpha (T

160 of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), IL-1beta, and interferon-gamma (IF

161 s had less severe illness); and (3) elevated interleukin-6 (IL-6), IL-8, and myeloperoxidase levels i

162 rkers, including interferon beta (IFN-beta), interleukin-6 (IL-6), interleukin-6 receptor alpha (IL-6

163 The inflammatory cytokine, interleukin-6 (IL-6), is a critical mediator of HCC deve

164 er levels of tumor necrosis factor (TNF) and interleukin-6 (IL-6), more neutrophil recruitment, and a

165 in response to the proinflammatory cytokine interleukin-6 (IL-6), suggesting that MSH3 may be a shut

166 ine plasma levels of 4 inflammatory markers (interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-a

167 s of depression and inflammatory biomarkers [interleukin-6 (IL-6), Tumor Necrosis Factor-Alpha (TNF-a

168 ercentage of 76.0.% The associated cytokines interleukin-6 (IL-6), tumor necrosis factor-alpha, and I

169 matory markers, C-reactive protein (CRP) and interleukin-6 (IL-6).

170 slet-derived protein 3alpha (REG3alpha), and interleukin-6 (IL-6).

171 of crucial autocrine factors, in particular, interleukin-6 (IL-6).

172 epressed mood and proinflammatory cytokines (interleukin-6 (IL-6); tumor necrosis factor-alpha (TNF))

173 red parasite biomass, systemic inflammation (interleukin 6 [IL-6]), endothelial activation (angiopoie

174 pondin 2; intercellular adhesion molecule 1; interleukin 6 [IL-6]; stromal cell-derived factor 1; tis

175 e regulator of inflammatory cytokines (e.g., interleukin-6 [IL-6] and IL-10), in mycobacterial infect

176 cium binding adaptor molecule-1 [Iba-1]) and interleukin-6 [IL-6]) and astrogliosis/astrocyte damage

177 that endothelial cell-derived factors (e.g., interleukin-6 [IL-6]) promote self-renewal of dental pul

178 anscription or secretion of proinflammatory (interleukin-6 [IL-6], granulocyte-macrophage colony-stim

179 nd production of six inflammatory molecules (interleukin-6 [IL-6], tumor necrosis factor alpha [TNFal

180 plasma levels of four inflammatory markers (interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-a

181 Corticosteroids inhibited Interleukin-6(IL-6) production (P = 0.0215) but did not

182 The molecular underpinnings of interleukin-6(IL-6)-blockade refractory patients remain

183 marker genes interleukin 1beta (IL1beta) and interleukin 6 (IL6) along with the M2 markers arginase-1

184 mote pro-inflammatory response by increasing interleukin 6 (IL6) expression and impede reparative res

185 fection, expressing proinflammatory cytokine interleukin 6 (IL6) mRNA, which was subsequently also ob

186 It is established that interleukin 6 (IL6) regulates multiple aspects of metabo

187 IVs who were breastfed, levels of sCD163 and interleukin 6 (IL6) were higher than levels in PHIV who

188 hogenicity genes (thrombospondin 1-(THBS 1), interleukin 6 (IL6), and arginine decarboxylase 2 (ADC2)

189 re; Egfr(f/f) mice had reduced expression of interleukin 6 (IL6), and epithelial STAT3 activation was

190 5 II), human epididymis protein 4 (HE4), and interleukin 6 (IL6), with limits of detection (LOD) as l

191 cy of tumor necrosis factor alpha-producing, interleukin 6 (IL6)-producing, and IL17-producing cells

192 pathway and by the proinflammatory cytokine interleukin 6 (IL6).

193 The cytokine interleukin-6 (IL6) and its downstream effector STAT3 co

194 lls (CA-MSC) produce not only high levels of interleukin-6 (IL6) but also the related cytokine leukem

195 is associated with poor survival in HCC and interleukin-6 (IL6) expression.

196 ate immune system, quantifiable as increased interleukin-6 (IL6) levels.

197 cts of high-sensitive C-reactive protein and interleukin-6 (IL6) measured in blood were related to ob

198 Furthermore, interleukin-6 (IL6), IL17, IGFBP4, and MMP13 were signif

199 ammatory molecules CC chemokine ligand 2 and interleukin 6 in diseased gingival tissues.

200 ic antibodies enables quantification of anti-interleukin 6 in plasma with high sensitivity.

201 LOY was modestly inversely associated with interleukin 6 in postmenopausal women (P = 0.03).

202 s between larger volume and higher levels of interleukin 6 in probands was also observed.

203 ity and has been successfully used to detect interleukin-6 in blood samples collected from patients s

204 trial, blocking the activity of the cytokine interleukin-6 in vivo prevented systemic inflammation an

205 idine triphosphate nucleotidohydrolase in an interleukin 6-independent manner.

206 PCR deficiency attenuated the elaboration of interleukin-6, infiltration of macrophages, and neoangio

207 ising therapies, including antiviral agents, interleukin-6 inhibitors, and convalescent serum.

208 Higher levels of C-reactive protein, interleukin-6, intercellular adhesion molecule-1, solubl

209 B, alpha-II-spectrin breakdown product 150, interleukin 6, interleukin 1 receptor antagonist, and c-

210 inflammatory biomarkers (C-reactive protein, interleukin 6, interleukin 10, tumor necrosis factor alp

211 ed SAMHD1 and proinflammatory cytokines (eg, interleukin 6, interleukin 1beta, and tumor necrosis fac

212 of proinflammatory cytokines (interleukin-3, interleukin-6, interleukin-13, interleukin-17, macrophag

213 phenotype, reflected by the up-regulation of interleukin-6, interleukin-1beta, bone sialoprotein, ost

214 al injury (angiopoietin-2) and inflammation (interleukin-6, interleukin-8, and interleukin-33 and sol

215 nes (e.g., interleukin-1beta, interleukin-2, interleukin-6, interleukin-8, and monocyte chemoattracta

216 ceptor expressed on myeloid cells [sTREM-1], interleukin-6, interleukin-8, chitinase-3-like protein-1

217 a 24-hour period, including interleukin-1RA, interleukin-6, interleukin-8, G-CSF, and M-CSF (p < 0.00

218 A group consisting of interleukin-6, interleukin-8, interleukin-10, and fracta

219 Interleukin-6, interleukin-8, interleukin-10, interleuki

220 ls of interleukin-1beta, interleukin-1alpha, interleukin-6, interleukin-8, interleukin-10, interleuki

221 higher expression of nuclear factor kappa B, interleukin-6, interleukin-8, transforming growth factor

222 er N-acetyl-l-cysteine reduced the levels of interleukin-6, interleukin-8/C-X-C motif chemokine ligan

223 Interleukin-6 is a cytokine critical to proinflammatory

224 Mutational patterns confirm that the interleukin-6-JAK1-STAT3 pathway is deregulated.

225 erformed studies with C57Bl6-J (control) and interleukin 6-knockout mice.

226 Here, we assessed inflammation by indexing interleukin-6 level in blood and measured psychomotor sp

227 , N-terminal pro B-type natriuretic peptide, interleukin-6 level, and D-dimers.

228 We compared D-dimer, soluble CD14, and interleukin 6 levels before and 12 months after antiretr

229 Interleukin 6 levels were higher and IL-10 levels were l

230 ice and found that aging led to elevated IL (interleukin)-6 levels and mitochondrial dysfunction, ass

231 alysis, the association of sodium levels and interleukin-6 levels (which has been linked to nonosmoti

232 Interleukin-6 levels 90 minutes after stress, and high-f

233 Higher interleukin-6 levels correlated with lower sodium levels

234 2, GSTP1, NPC1, NPC2, PSAP and SORL1 reduced interleukin-6 levels in astrocytes.

235 correlated with reactive oxygen species and interleukin-6 levels in response to Candida.

236 um lactate dehydrogenase, procalcitonin, and interleukin-6 levels.

237 n markers were suggestive of cytokine storm (interleukin-6 median, 135 pg/mL) and macrophage activati

238 secretion of tumor necrosis factor alpha and interleukin-6 mediated through TLR2 and TLR4 signaling.

239 onspecifically, likely through inhibition of interleukin 6-mediated signaling to B cells and plasma c

240 Elderly had significantly lower levels of interleukin-6, monocyte chemotactic protein-1, monocyte

241 ide significance, including 2 new loci: IL6 (interleukin 6) on 7p15.3 and ALPL (alkaline phosphatase)

242 LOY was modestly inversely associated with interleukin-6 only in postmenopausal women (p=0.04).

243 144 (77%), glucocorticoids in 91 (49%), and interleukin-6 or 1RA inhibitors in 38 (20%).

244 There was no significant effect on plasma interleukin-6 or D-dimer levels, nor on monocyte/T-cell

245 ritin (odds ratio [OR], 2.40; P < 0.001) and interleukin-6 (OR, 1.45; P = 0.009).

246 did not reduce levels of interleukin-1beta, interleukin-6, or C-reactive protein and did not result

247 e did not result in lower interleukin-1beta, interleukin-6, or C-reactive protein levels than placebo

248 levels of inflammatory cytokines, including interleukin-6, over baseline.

249 erivascular fibrillar collagen and pulmonary interleukin-6 overexpression discriminated rats that dev

250 efensin alpha 5 (P = 0.03) increased whereas interleukin-6 (P = 0.02) and serum LBP (P = 0.009) reduc

251 s demonstrated stimulation of interferon and interleukin-6 pathways in bronchoalveolar lavage samples

252 tic livers of beta2SP(+/-) mice treated with interleukin-6 (pIL6; (IL6) beta2SP(+/-) LSCs) were highl

253 CRP (C-reactive protein) and IL (interleukin)-6 plasma concentrations were measured immed

254 this infection such as C-reactive proteins, interleukin-6, procalcitonin and ferritin.

255 , midregional proadrenomedullin, cystatin-C, interleukin-6, procalcitonin, and others.

256 strongly suppress tumor necrosis factor and interleukin-6 production and compromise cell viability.

257 Moreover, thrombin- and histamine-stimulated interleukin-6 production required both TAB1-TAB2 and TAB

258 face proteins associated with maturation and interleukin-6 production.

259 Furthermore, elevated osteocyte TNF-alpha, interleukin-6, RANKL, OPG, and sclerostin corresponded w

260 r of tumor necrosis factor alpha (TNFalpha), interleukin 6 receptor (IL-6R), and epidermal growth fac

261 uble tumor necrosis factor receptor and anti-interleukin 6 receptor antibody induce long-term (>=1 ye

262 sp358Ala variant (rs2228145; A>C) in the IL (interleukin)-6 receptor ( IL6R) gene has been implicated

263 es to map integratively the epitope of human interleukin-6 receptor (IL-6R) for two adnectins with di

264 on gamma-induced protein 10 (IP-10), soluble interleukin-6 receptor (sIL-6R), sCD14, and sGP130-were

265 -1 receptor antagonist (IL-1Ra), and soluble interleukin-6 receptor (sIL-6R).

266 feron beta (IFN-beta), interleukin-6 (IL-6), interleukin-6 receptor alpha (IL-6Ralpha), soluble inter

267 lations, the safety and efficacy of the anti-interleukin-6 receptor antibody tocilizumab in patients

268 eukin-6 receptor alpha (IL-6Ralpha), soluble interleukin-6 receptor beta (sIL-6Rbeta, or gp130), IL-8

269 The efficacy of interleukin-6 receptor blockade in hospitalized patients

270 gle variant, as did plasma concentrations of interleukin-6 receptor subunit alpha (also based on a si

271 humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in p

272 uated glutamate uptake, intramyelinic edema, interleukin-6 release, complement activation, inflammato

273 uced nuclear levels of phosphorylated STAT3, interleukin 6 secretion, foam cell formation, and lipid

274 ect to inhibiting lipopolysaccharide-induced interleukin-6 secretion in human macrophages, but its ab

275 to play a role in regulating CSR through the interleukin-6 signaling pathway and in proper IgA expres

276 Interleukin-6 significantly correlated with alveolar bon

277 mma, myeloperoxidase, tumor necrosis factor, interleukin 6, soluble CD14).

278 ing pressure and the plasma concentration of interleukin-6, soluble receptor for advanced glycation e

279 igher AT1RaAbs correlated significantly with interleukin-6 (Spearman r=0.33, P<0.0001), systolic bloo

280 ological indicator of maternal inflammation (interleukin-6) that has been shown to influence fetal br

281 protein 1, tumor necrosis factor alpha, and interleukin 6) through YAP association with the TEA doma

282 ion of pro-inflammatory cytokines (including interleukin-6, tumor necrosis factor-alpha and interleuk

283 astrocyte activation, and interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and interleu

284 evels of pro-inflammatory factors, including interleukin-6, tumor necrosis factor-alpha, and matrix m

285 higher markers of inflammation (ferritin and interleukin-6 values).

286 an also directly activate KSHV-encoded viral interleukin-6 (vIL-6) and, thus, contribute to the patho

287 data demonstrate that the KSHV protein viral interleukin-6 (vIL-6) can induce integrin beta3 in an in

288 Human herpesvirus 8 (HHV-8) viral interleukin-6 (vIL-6) is a cytokine that is poorly secre

289 KSHV viral interleukin-6 (vIL-6) is a viral homolog of human IL-6 (

290 KSHV-encoded viral interleukin-6 (vIL-6) is implicated in the development o

291 Human herpesvirus 8 (HHV-8) viral interleukin-6 (vIL-6) localizes largely to the endoplasm

292 CE Human herpesvirus 8 (HHV-8)-encoded viral interleukin-6 (vIL-6) was the first viral IL-6 homologue

293 ytic replication and directly activate viral interleukin-6 (vIL-6).

294 ive aptasensor for quantitative detection of interleukin-6 was developed by using a glassy carbon ele

295 A thio-terminated aptamer specific for interleukin-6 was immobilized on the surface of the modi

296 ophil gelatinase-associated lipocalin 1, and interleukin 6 were also assessed.

297 ide-binding protein, C-reactive protein, and interleukin 6 were differentially expressed between coun

298 Male sex and higher interleukin-6 were significantly associated with lower M

299 serum monocyte chemoattractant protein-1 and interleukin-6 were significantly increased.

300 luble tumor necrosis factor-receptor I], and interleukin-6), YKL-40 (related to liver injury and infl